Corvus Pharmaceuticals, Inc. (CRVS) Misses Q2 EPS by 4c

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q2 EPS of ($0.19), $0.04 worse than the analyst estimate of ($0.15).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• IREN (IREN) Reiterated at Market Outperform by Citizens as Cloud Business Gains Momentum
• Deutsche Bank Upgrades Ningbo Xusheng Group Co Ltd (603305:CH) to Hold
• JPMorgan Upgrades Magellan Financial Group (MFG:AU) (MGLLF) to Neutral